A trial vaccine has succeeded in generating low levels of antibodies needed to target HIV. It’s a first but much-needed step toward preventing infection.
from Feed: All Latest https://ift.tt/ZJ3pqzC
via IFTTT
from Feed: All Latest https://ift.tt/ZJ3pqzC
via IFTTT